• PDF: Delivered by email usually within 12 to 48 UK business hours.

The Future of HIV Therapeutics
Market Forecasts to 2015

  • Publication Date:December 2009
  • Publisher:GBI Research
  • Product Type: Report
  • Pages:101

The Future of HIV Therapeutics Market Forecasts to 2015

The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Summary

GBI Research, the leading business intelligence provider, has released its latest research ""The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis."" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global HIV therapeutics market. The report analyzes the markets for HIV therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data for the HIV therapeutics market from 2000 to 2008, forecast forward to 2015
  • Analysis of the HIV therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Global HIV Therapeutics Market: Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Global HIV Therapeutics Market: Overview
    • 3.1 Disease Overview
    • 3.2 Market Overview
  • 4 Global HIV Therapeutics Market: Market Characterization
    • 4.1 Market Forecasts
    • 4.2 Branded Versus Generics
    • 4.3 Average Cost of Therapy
    • 4.4 Volume
    • 4.5 Usage Patterns
      • 4.5.1 Diseased Population
      • 4.5.2 Treatment Seeking Population
      • 4.5.3 Diagnosis Population
      • 4.5.4 Prescription Population
      • 4.5.5 Usage Patterns
      • 4.5.6 Geographical Distribution
    • 4.6 HIV Therapeutics Market: Drivers and Restraints
    • 4.7 Market Drivers
      • 4.7.1 Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population
      • 4.7.2 New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake
      • 4.7.3 Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering Impact of Generics
    • 4.8 Market Restraints
      • 4.8.1 Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions
      • 4.8.2 Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base
      • 4.8.3 Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to Reduction in Drug Volumes
    • 4.9 Market Trend
      • 4.9.1 Incidence and Prevalence Rates are Increasing at a Slow Rate
      • 4.9.2 Many New Companies are Actively Pursuing Different Classes of Drugs in Their Pipeline
      • 4.9.3 Although DTC Advertising is Aimed at Increasing Awareness, it is Attracting Criticism for Incorrect Depiction of Therapeutic Benefits of Treatment Options
      • 4.9.4 Current Reimbursement Scenario is Positive for HIV as Countries Reimburse Almost All of the Costs Associated with HIV Drugs
      • 4.9.5 Regulatory Scenario for HIV Drugs is Positive and Many Countries Facilitate Quicker Review for HIV Drug Applications
  • 5 Global HIV Therapeutics Market: The US Market
    • 5.1 Market Forecasts
    • 5.2 Average cost of Therapy
    • 5.3 Volume
    • 5.4 Usage Patterns
      • 5.4.1 Diseased Population
      • 5.4.2 Treatment Seeking Population
      • 5.4.3 Diagnosis Population
      • 5.4.4 Prescription Population
      • 5.4.5 Usage Patterns
  • 6 Global HIV Therapeutics Market: Europe Market
    • 6.1 Market Forecasts
    • 6.2 Average Cost of Therapy
    • 6.3 Volume
    • 6.4 Usage patterns
      • 6.4.1 Diseased Population
      • 6.4.2 Treatment Seeking Population
      • 6.4.3 Diagnosis Population
      • 6.4.4 Prescription Population
      • 6.4.5 Usage Patterns
  • 7 Global HIV Therapeutics Market: Japan Market
    • 7.1 Market Forecasts
    • 7.2 Average Cost of Therapy
    • 7.3 Volume
    • 7.4 Usage Patterns
      • 7.4.1 Diseased Population
      • 7.4.2 Treatment Seeking Population
      • 7.4.3 Diagnosis Population
      • 7.4.4 Prescription Population
      • 7.4.5 Usage Patterns
  • 8 Global HIV Therapeutics Market: Unmet Need
    • 8.1 Different Classes of Drugs
      • 8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
      • 8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • 8.1.3 Protease Inhibitors
      • 8.1.4 Viral Fusion (or Entry) Inhibitors
      • 8.1.5 HIV Integrase Strand Transfer Inhibitors
      • 8.1.6 Multi-class Combination Products
    • 8.2 Unmet Need Analysis
      • 8.2.1 HIV Drugs are Low in Efficacy as None of the Drugs Provide a Cure for the Disease However Newer Multi Class Combination Drugs Can Achieve Undetectable Level of HIV
      • 8.2.2 When Compared to the Adverse Symptoms of HIV Infection Progression, the HIV Medications are Relatively Safe and Have Serious Side Effects Rarely
      • 8.2.3 Average Cost of HIV Therapy is High, Leading to a Need for a More Cost Effective Treatment Option
    • 8.3 Pipeline Analysis
      • 8.3.1 Phase I
      • 8.3.2 Phase II
      • 8.3.3 Phase III
  • 9 Global HIV Therapeutics Market: Competitive Landscape
    • 9.1 Evolving Competitive Landscape
    • 9.2 Market Share Analysis
      • 9.2.1 Atripla, Truvada and Isentress are the HIV brands that will Drive the Market and Competition
    • 9.3 Key Product Analysis
      • 9.3.1 Truvada
      • 9.3.2 Atripla
      • 9.3.3 Viread
      • 9.3.4 Isentress
      • 9.3.5 Trizivir
      • 9.3.6 Kaletra
      • 9.3.7 Reyataz
      • 9.3.8 Combivir
      • 9.3.9 Epzicom/Kivexa
      • 9.3.10 Sustiva Franchise
    • 9.4 Competitive Profiling
      • 9.4.1 Gilead
      • 9.4.2 GlaxoSmithKline (GSK)
      • 9.4.3 Bristol-Myers Squibb (BMS)
      • 9.4.4 Abbott Laboratories
      • 9.4.5 Merck
      • 9.4.6 Pfizer
  • 10 Global HIV Therapeutics Market: Strategic Consolidations
    • 10.1 Overview
      • 10.1.1 Total Deals by Type and Geography
    • 10.2 Mergers and Acquisitions
    • 10.3 Licensing Agreements
      • 10.3.1 Preclinical
      • 10.3.2 Phase II
      • 10.3.3 Phase III
      • 10.3.4 Approved
  • 11 Global HIV Therapeutics Market: Conclusion
  • 12 Global HIV Therapeutics Market: Appendix
    • 12.1 Market Definitions
    • 12.2 Abbreviations
    • 12.3 Research Methodology
      • 12.3.1 Coverage
      • 12.3.2 Secondary Research
      • 12.3.3 Primary Research
      • 12.3.4 Forecasts
      • 12.3.5 Expert Panel Validation
    • 12.4 Contact Us
    • 12.5 Disclaimer
    • 12.6 Sources
  • List of Tables
    • Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2000–2008
    • Table 2: HIV Market, Global, Revenue ($m), 2008–2015
    • Table 3: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2000–2008
    • Table 4: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2008–2015
    • Table 5: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008
    • Table 6: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
    • Table 7: HIV Therapeutics Market, Global, Volume (million), 2000–2008
    • Table 8: HIV Therapeutics Market, Global, Volume (million), 2008–2015
    • Table 9: HIV Therapeutics Market, Global, Diseased Population, 2000–2008
    • Table 10: HIV Therapeutics Market, Global, Diseased Population, 2008–2015
    • Table 11: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000–2008
    • Table 12: HIV Therapeutics Market, Global, Treatment Seeking Population, 2008–2015
    • Table 13: HIV Therapeutics Market, Global, Diagnosis Population, 2000–2008
    • Table 14: HIV Therapeutics Market, Global, Diagnosis Population, 2008–2015
    • Table 15: HIV Therapeutics Market, Global, Prescription Population, 2000–2008
    • Table 16: HIV Therapeutics Market, Global, Prescription Population, 2008–2015
    • Table 17: HIV Therapeutics Market, Global, Usage Patterns, 2000–2008
    • Table 18: HIV Therapeutics Market, Global, Usage Patterns, 2008–2015
    • Table 19: HIV Therapeutics Market, Global, Market Drivers, 2008
    • Table 20: HIV Therapeutics Market, Global, Market Restraints, 2008
    • Table 21: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2008–15
    • Table 22: HIV Therapeutics Market, US, Revenues ($m), 2000–2008
    • Table 23: HIV Therapeutics Market, US, Revenue ($m), 2008–2015
    • Table 24: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000–2008
    • Table 25: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2008–2015
    • Table 26: HIV Therapeutics Market, US, Volume (million), 2000–2008
    • Table 27: HIV Therapeutics Market, US, Volume (million), 2008–2015
    • Table 28: HIV Therapeutics Market, US, Diseased Population, 2000–2008
    • Table 29: HIV Therapeutics Market, US, Diseased Population, 2008–2015
    • Table 30: HIV Therapeutics Market, US, Treatment Seeking Population, 2000–2008
    • Table 31: HIV Therapeutics Market, US, Treatment Seeking Population, 2008–2015
    • Table 32: HIV Therapeutics Market, US, Diagnosis Population, 2000–2008
    • Table 33: HIV Therapeutics Market, US, Diagnosis Population, 2008–2015
    • Table 34: HIV Therapeutics Market, US, Prescription Population, 2000–2008
    • Table 35: HIV Therapeutics Market, US, Prescription Population, 2008–2015
    • Table 36: HIV Therapeutics Market, US, Usage Patterns, 2000–2008
    • Table 37: HIV Therapeutics Market, US, Usage Patterns, 2008–2015
    • Table 38: HIV Therapeutics Market, Europe, Revenues ($m), 2000–2008
    • Table 39: HIV Therapeutics Market, Europe, Revenue ($m), 2008–2015
    • Table 40: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2000–2008
    • Table 41: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2008–2015
    • Table 42: HIV Therapeutics Market, Europe, Volume (million), 2000–2008
    • Table 43: HIV Therapeutics Market, Europe, Volume (million), 2008–2015
    • Table 44: HIV Therapeutics Market, Europe, Diseased Population, 2000–2008
    • Table 45: HIV Therapeutics Market, Europe, Diseased Population, 2008–2015
    • Table 46: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000–2008
    • Table 47: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2008–2015
    • Table 48: HIV Therapeutics Market, Europe, Diagnosis Population, 2000–2008
    • Table 49: HIV Therapeutics Market, Europe, Diagnosis Population, 2008–2015
    • Table 50: HIV Therapeutics Market, Europe, Prescription Population, 2000–2008
    • Table 51: HIV Therapeutics Market, Europe, Prescription Population, 2008–2015
    • Table 52: HIV Therapeutics Market, Europe, Usage Patterns, 2000–2008
    • Table 53: HIV Therapeutics Market, Europe, Usage Patterns, 2008–2015
    • Table 54: HIV Therapeutics Market, Japan, Revenue ($m), 2000–2008
    • Table 55: HIV Therapeutics Market, Japan, Revenue ($m), 2008–2015
    • Table 56: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000–2008
    • Table 57: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2008–2015
    • Table 58: HIV Therapeutics Market, Japan, Volume (million), 2000–2008
    • Table 59: HIV Therapeutics Market, Japan, Volume (million), 2008–2015
    • Table 60: HIV Therapeutics Market, Japan, Diseased Population, 2000–2008
    • Table 61: HIV Therapeutics Market, Japan, Diseased Population, 2008–2015
    • Table 62: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000–2008
    • Table 63: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2008–2015
    • Table 64: HIV Therapeutics Market, Japan, Diagnosis Population, 2000–2008
    • Table 65: HIV Therapeutics Market, Japan, Diagnosis Population, 2008–2015
    • Table 66: HIV Therapeutics Market, Japan, Prescription Population, 2000–2008
    • Table 67: HIV Therapeutics Market, Japan, Prescription Population, 2008–2015
    • Table 68: HIV Therapeutics Market, Japan, Usage Patterns, 2000–2008
    • Table 69: HIV Therapeutics Market, Japan, Usage Patterns, 2008–2015
    • Table 70: HIV Market, Global, Different Classes of Drugs
    • Table 71: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2008
    • Table 72: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2008
    • Table 73: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2008
    • Table 74: HIV Therapeutics Market, Global, Major Drugs and Manufacturers, 2008
    • Table 75: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008
    • Table 76: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008
    • Table 77: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008
    • Table 78: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008
    • Table 79: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008
  • List of Figures
    • Figure 1: HIV Therapeutics Market, Global, Market Overview, 2008
    • Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2015
    • Figure 3: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015
    • Figure 4: HIV Therapeutics Market, Global, Volume (million), 2000-2015
    • Figure 5: HIV Therapeutics Market, Global, Diseased Population, 2000–2015
    • Figure 6: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000–2015
    • Figure 7: HIV Therapeutics Market, Global, Diagnosis Population, 2000–2015
    • Figure 8: HIV Therapeutics Market, Global, Prescription Population, 2000–2015
    • Figure 9: HIV Therapeutics Market, Global, Usage Patterns, 2000–2015
    • Figure 10: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2000–2015
    • Figure 11: HIV Therapeutics Market, Global, Geographical Outlook, 2008
    • Figure 12: HIV Therapeutics Market, Global, Market Indicators, 2008
    • Figure 13: HIV Therapeutics Market, Global, Key Market Events, 2008–2015
    • Figure 14: HIV Therapeutics Market, US, Revenue ($m), 2000–2015
    • Figure 15: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000–2015
    • Figure 16: HIV Therapeutics Market, US, Volume (million), 2000–2015
    • Figure 17: HIV Therapeutics Market, US, Diseased Population, 2000–2015
    • Figure 18: HIV Therapeutics Market, US, Treatment Seeking Population, 2000–2015
    • Figure 19: HIV Therapeutics Market, US, Diagnosis Population, 2000–2015
    • Figure 20: HIV Therapeutics Market, US, Prescription Population, 2000–2015
    • Figure 21: HIV Therapeutics Market, US, Usage Patterns, 2000–2015
    • Figure 22: HIV Therapeutics Market, Europe, Revenue ($m), 2000–2015
    • Figure 23: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 2000–2015
    • Figure 24: HIV Therapeutics Market, Europe, Volume (million), 2000–2015
    • Figure 25: HIV Therapeutics Market, Europe, Diseased Population, 2000–2015
    • Figure 26: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000–2015
    • Figure 27: HIV Therapeutics Market, Europe, Diagnosis Population, 2000–2015
    • Figure 28: HIV Therapeutics Market, Europe, Prescription Population, 2000–2015
    • Figure 29: HIV Therapeutics Market, Europe, Usage Patterns, 2000–2015
    • Figure 30: HIV Therapeutics Market, Japan, Revenue ($m), 2000–2015
    • Figure 31: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000–2015
    • Figure 32: HIV Therapeutics Market, Japan, Volume (million), 2000–2015
    • Figure 33: HIV Therapeutics Market, Japan, Diseased Population, 2000–2015
    • Figure 34: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000–2015
    • Figure 35: HIV Therapeutics Market, Japan, Diagnosis Population, 2000–2015
    • Figure 36: HIV Therapeutics Market, Japan, Prescription Population, 2000–2015
    • Figure 37: HIV Therapeutics Market, Japan, Usage Patterns, 2000–2015
    • Figure 38: HIV Therapeutics Market, Global, Analysis of Unmet Needs for Major Drug Class, 2008
    • Figure 39: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2008
    • Figure 40: HIV Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues, 2006-08
    • Figure 41: HIV Therapeutics Market, Global, Competitive Analysis of Top 4 Manufacturers, 2006–08
    • Figure 42: HIV Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
    • Figure 43: HIV Therapeutics Market, Global, Benchmark of Top 10 Brands – 2008
    • Figure 44: HIV Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2009
    • Figure 45: HIV Therapeutics Market, GSK, HIV Revenue as Percentage of Total Revenue, 2009
    • Figure 46: HIV Therapeutics Market, BMS, HIV Revenue as Percentage of Total Revenue, 2009
    • Figure 47: HIV Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2009
    • Figure 48: HIV Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2009
    • Figure 49: HIV Therapeutics Market, Global, Deals by Geography and Type, 2008
    • Figure 50: HIV Therapeutics Market, Global, M&A Deals, 2008
    • Figure 51: HIV Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-09
    • Figure 52: GBI Research Methodology
    • Figure 53: GBI Research Market Forecasting Model
+44 20 8816 8548

Ask a question about The Future of HIV Therapeutics

Enter the characters you see in the picture below
Captcha